• Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

  NCT00977483

  CompletedInterventionalPhase 3Updated Feb 7, 2022
• Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

  NCT00328601

  CompletedInterventionalPhase 3Updated Feb 7, 2022
• A Study To Evaluate the Safety, Tolerance, Pharmacokinetics/Pharmacodynamics and Efficacy of SYHA1402 Tablets For the Treatment of Patients With Diabetic Peripheral Neuropathy in China

  NCT05116111

  Unknown statusInterventionalPhase 2Updated Nov 12, 2021
• Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy

  NCT03914404

  CompletedInterventionalPhase 4Updated Apr 16, 2019
• Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

  NCT00760955

  CompletedInterventionalPhase 2Updated Jun 22, 2016
• Study of DA-9801 to Treat Diabetic Neuropathic Pain

  NCT01813799

  CompletedInterventionalPhase 2Updated Apr 16, 2019

ClinicalTrials.gov ID

NCT01224353

Lead Sponsor

NovaMed Pharmaceuticals Inc.INDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2Phase 3

Enrollment

200Estimated

Last Update Posted

Oct 21, 2010Estimated

Start Date

Nov 2010

Primary Completion Date

May 2011Estimated

Completion Date

Jul 2011Estimated

Official Title

Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy

Brief Summary

The purpose of the study is to evaluate the efficacy on overall neuropathic sensory symptom improvement of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with distal symmetric polyneuropathy (DSP).

• Diabetics

• lipoic acid
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Subjects must fulfil all of the following criteria to be appropriate to enter into Registry (Visit 2)

  1. Provision of informed consent
  2. Females and males aged from 18 to 75 (inclusive), who were definitely diagnosed with diabetes
  3. HbA1C< 10％
  4. Moderate neuropathy according to Neuropathy Disability Score (NDS) >= 4 points. Difference in score between left and right foot is not to be higher than 2 points
  5. Total Symptom Score (TSS) > 6.5 points
  6. At least one of the four symptoms of the TSS has occurred continuously over the last 3 months before screening
  7. Other concomitant treatments (the drugs and their dosage) have been stable over 1 month before screening Subjects must fulfil all of the following criteria before randomization：
  8. TSS > 5 points
  9. TSS range (maximum TSS - minimum TSS during Run-in Period) < 3 points during the Run-in Period
  10. Compliance in Run-in Period > 85%

Exclusion Criteria:

1. Neurologic disease other than diabetic neuropathy that may produce weakness, sensory loss, or autonomic symptoms or test abnormality
2. Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers
3. Patients who have been hospitalized due to glucopenia or ketoacidosis in the last 3 month
4. Present ulcers on lower limbs of any cause
5. Antioxidant therapy within the last 1 month before screening (Vitamin E> 400IU, Vitamin C> 200mg once daily for continuous 2 weeks)
6. Any ALA therapy within the last1 month before screening
7. Opioid analgesic therapy within the last 1 month before screening
8. History of mental, psychological or behavioral conditions rendering the patient unable to follow the protocol
9. History of malignant tumors in the past 5 years except for basal cell carcinoma
10. Any severe systematic diseases, at the investigator's discretion, which will make it undesirable for the patient to participate in the trial or which could jeopardize compliance with the trial protocol,
11. ALT or AST > 2.5 ´ upper limit of reference range
12. Cr > 1.8mg/dL ( > 159µmol/L) for males or > 1.6mg/dL ( > 141µmol/L) for females
13. History of hypersensitive to the active ingredients or excipients of ALA
14. Participation in a clinical study or treatment with a non-approved experimental medication in the last 1 month
15. Pregnant or breast-feeding women, or women of childbearing age without appropriate contraception measures

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

NovaMed Pharmaceuticals Inc.INDUSTRY

kkyynn2008@yahoo.cn86 051267727501 ext. 3503